Drugs / SF-MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05261360 | Mar 2022 → Mar 2024 | osteoarthritis, knee | Eskisehir Osmangazi University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SF-MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05261360 ↗ |
| Modality | Cell therapy | “synovial fluid-derived mesenchymal stem cells” NCT05261360 ↗ |
| Route | Other | “by intra-articular injection method” NCT05261360 ↗ |